Abbott to distribute MSD's diabetes drug in India
Leveraging its broad footprint in the country Abbott will distribute the portfolio. The products are marketed under brand names Januvia, Janumet and Janumet XR, the companies said in a joint statement.
Sitagliptin is a Dipeptidyl Peptidase IV Inhibitors used for treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity, they said.
'Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health,' V-P of Abbott in India Ambati Venu said.
MSD India Region Managing Director Rehan A. Khan said, 'Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
11 hours ago
- News18
Abbott launches glucose reading device with smartphone connectivity
Last Updated: New Delhi, Aug 21 (PTI) Healthcare firm Abbott on Thursday launched in India its FreeStyle Libre 2 Plus sensor device that offers automatic glucose readings every minute on a smartphone, aimed to help diabetic patients manage their condition. People living with diabetes can monitor their glucose readings without having to scan and receive alerts automatically on their compatible smartphones during low or high glucose levels, helping them make informed decisions, the company said in a statement. Abbott Regional Medical Affairs Director, Asia Pacific, Diabetes Division, Kenneth Lee, said the company's pioneering FreeStyle Libre technology is transforming the way diabetes is managed for over seven million individuals globally. view comments First Published: August 21, 2025, 17:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
Time of India
a day ago
- Time of India
Hyderabad among top 7 life sciences clusters globally
Hyderabad: Telangana's thriving life sciences sector has propelled Hyderabad into one of the top seven life sciences clusters in the world and the only Indian city to achieve this distinction, IT & industries minister Duddilla Sridhar Babu said on Wednesday. Tired of too many ads? go ad free now He said the sector attracted investments worth Rs 54,000 crore since Dec 2023, resulting in the creation of 2 lakh new jobs in pharmaceutical manufacturing, medical technology, and vaccine production. Pointing out that global giants such as Eli Lilly, Amgen, MSD, Zoetis, Evernorth, and Olympus have already chosen Hyderabad as their preferred GCC hub, he said Telangana will soon unveil its next-gen life sciences policy, which will be a "cutting-edge policy framework designed to attract large-scale investments." Sridhar Babu also said the state set an ambitious target to scale up its life sciences economy to $250 billion by 2030, with an eye on making Telangana the life sciences capital of Asia. The minister, who chaired the 6th board meeting of the Telangana Life Sciences Foundation in the city during the day, also proposed the preparation of a feasibility report for establishing the Telangana School of Life Sciences. The foundation's board members include Dr Reddy's Laboratories Chairman Satish Reddy, Laurus Labs CEO Dr Satyanarayana Chava, special chief secretary Sanjay Kumar, and Telangana life sciences director Shakti Nagappan.
Time of India
4 days ago
- Time of India
Docs save life with rare heart valve procedure
New Delhi: A 72-year-old woman battling breathlessness, chest pain and severe fatigue - 14 years after undergoing major heart surgery - was given a new lease on life through a rare and risky intervention performed at Apollo Hospitals . Back then, she survived acute aortic dissection with a complex surgery that replaced her damaged aortic valve and root with a tissue valve. Over the years, that valve narrowed dangerously, demanding urgent replacement. Normally this could be managed through a minimally invasive Transcatheter Aortic Valve Implantation (TAVI) via the femoral artery in the leg. However, her situation was far from routine - a chronic Type B aortic dissection left her aorta with two channels, a "true" and a "false" lumen, the latter being larger. This made reaching the heart with catheters extremely risky. Open-heart surgery was ruled out due to the high danger posed by her age, frailty and the residual dissection. Faced with these obstacles, a multidisciplinary team from Apollo's Heart Valve and Aortic Program - led by Dr. Gautam Naik and Dr. Niranjan Hiremath - devised a plan for a rare and complex trans-femoral Valve-in-Valve TAVI procedure . Such cases have been reported only in isolated instances worldwide. After meticulous planning and advanced imaging guidance, the 3.5-hour procedure was performed entirely through the femoral artery. A 23 mm Navitor Vision (Abbott) transcatheter heart valve was successfully implanted, restoring healthy blood flow. The patient recovered well and was discharged in stable condition on the fifth day. A minor new false lumen detected after the procedure was managed conservatively with strict blood pressure control. "In complex heart disease, success often depends on finding safe, innovative solutions tailored to the patient," said Dr. Naik.
